Hemophagocytic Lymphohistiocytosis Market Report 2026

The hemophagocytic lymphohistiocytosis market size has grown strongly in recent years. It will grow from $2.44 billion in 2025 to $2.59 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to improvements in critical care management, increased clinical awareness of rare immune disorders, expansion of diagnostic testing capabilities, availability of chemotherapy-based treatment regimens, growth in specialized hospital units.

The hemophagocytic lymphohistiocytosis market size is expected to see strong growth in the next few years. It will grow to $3.24 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing research into targeted immunotherapies, rising adoption of precision diagnostics, expansion of early intervention strategies, growing focus on rare disease management, increasing development of novel treatment protocols. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, rising use of targeted immunosuppressive therapies, growing focus on rapid diagnostic protocols, expansion of specialized hlh treatment centers, enhanced integration of multidisciplinary care models.

The rising prevalence of autoimmune diseases is expected to drive the growth of the hemophagocytic lymphohistiocytosis (HLH) market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells and tissues. Factors contributing to the increasing prevalence include genetic predisposition, environmental triggers, infections, hormonal changes, and greater early diagnosis and awareness. HLH treatments support autoimmune patients by suppressing excessive immune activation, reducing inflammation, and restoring immune system balance, thereby alleviating severe immune-mediated complications and improving overall disease management. For example, in February 2024, Arthritis Australia, a non-profit organization, reported that in 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Consequently, the growing prevalence of autoimmune diseases is fueling HLH market growth.

Increasing healthcare expenditure is also expected to propel the growth of the HLH market. Healthcare expenditure represents the total spending on medical goods, services, and public health programs within a country or region. Rising healthcare costs are driven by factors such as aging populations, the growing burden of chronic diseases, medical advancements, higher service costs, and increased demand for improved care. Higher healthcare spending supports HLH treatments by funding advanced diagnostics, therapies, and research, enhancing access to specialized care, improving patient outcomes, and facilitating the development of new therapies and early detection methods. For instance, in April 2025, the UK Office for National Statistics reported that total healthcare expenditure grew by 6.5% in nominal terms between 2023 and 2024, compared with 6.3% growth in 2023.

Key companies in the HLH market are developing advanced therapies, including monoclonal antibody treatments, to selectively target and deplete pathogenic immune cells. Monoclonal antibody therapy uses laboratory-made antibodies designed to recognize specific antigens on cells to modulate immune responses or treat diseases. For example, in October 2024, Electra Therapeutics, Inc., a U.S.-based biotechnology company, launched ELA026, which received Orphan Drug Designation (ODD) from the FDA for treating HLH. ELA026 is a first-in-class antibody therapy targeting signal regulatory proteins (SIRP), offering a novel approach for secondary HLH (sHLH), a rare and life-threatening condition with no approved treatments.

Major companies operating in the hemophagocytic lymphohistiocytosis market are Labcorp, Quest Diagnostics Incorporated, Electra Therapeutics Inc., Swedish Orphan Biovitrum AB, ARUP Laboratories, Invitae Corp., Mayo Clinic Laboratories, Metropolis Healthcare, Centogene NV, Fulgent Genetics, Atara Biotherapeutics Inc., Innate Pharma S.A., Blueprint Genetics, Novimmune SA, Machaon Diagnostics Inc., SeaStar Medical Inc., AB2 Bio Ltd., Elixiron Immunotherapeutics Inc., Bellicum Pharmaceuticals Inc., Eurofins Biomnis.

North America was the largest region in the hemophagocytic lymphohistiocytosis market in 2025. The regions covered in the hemophagocytic lymphohistiocytosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemophagocytic lymphohistiocytosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hemophagocytic lymphohistiocytosis market by increasing costs of imported diagnostic kits, genetic testing reagents, immunosuppressive drugs, chemotherapy agents, and laboratory instruments. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported rare-disease diagnostics and therapies, while Asia-Pacific faces higher treatment input costs. These tariffs are contributing to increased treatment expenses and procurement delays. However, they are also encouraging domestic diagnostic development, local pharmaceutical manufacturing, and expanded regional research capabilities for rare immune disorders.

The hemophagocytic lymphohistiocytosis market research report is one of a series of new reports that provides hemophagocytic lymphohistiocytosis market statistics, including hemophagocytic lymphohistiocytosis industry global market size, regional shares, competitors with a hemophagocytic lymphohistiocytosis market share, detailed hemophagocytic lymphohistiocytosis market segments, market trends and opportunities, and any further data you may need to thrive in the hemophagocytic lymphohistiocytosis industry. This hemophagocytic lymphohistiocytosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disorder caused by excessive immune activation, resulting in severe inflammation and multi-organ failure. The primary goal in managing HLH is to control the overactive immune response and prevent organ damage. Timely diagnosis and intervention are critical to improving survival outcomes.

The main types of HLH are familial and acquired. Familial HLH is an inherited disorder caused by genetic mutations that affect immune system regulation, emphasizing the role of genetics in developing targeted treatments. Diagnosis typically involves blood tests, bone marrow biopsy, genetic testing, and blood cultures, while treatment options include steroids, chemotherapy, antibiotics, antiviral drugs, and other therapies. HLH treatments are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are used by a range of end-users, including hospitals, home care services, specialty clinics, and others.

The hemophagocytic lymphohistiocytosis market consists of revenues earned by entities by providing services such as stem cell transplantation, supportive care, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophagocytic lymphohistiocytosis market includes sales of immunosuppressive drugs, intravenous immunoglobulin, and plasmapheresis equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.